日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Pelabresib联合ruxolitinib治疗JAK抑制剂初治骨髓纤维化:一项随机3期试验

Rampal, Raajit K; Grosicki, Sebastian; Chraniuk, Dominik; Abruzzese, Elisabetta; Bose, Prithviraj; Gerds, Aaron T; Vannucchi, Alessandro M; Palandri, Francesca; Lee, Sung-Eun; Gupta, Vikas; Lucchesi, Alessandro; Oh, Stephen T; Kuykendall, Andrew T; Patriarca, Andrea; Álvarez-Larrán, Alberto; Mesa, Ruben; Kiladjian, Jean-Jacques; Talpaz, Moshe; Scandura, Joseph M; Lavie, David; Harris, Morgan; Kays, Sarah-Katharina; Li, Qing; Boxhammer, Rainer; Brown, Barbara; Jegg, Anna-Maria; Harrison, Claire N; Mascarenhas, John

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

抗 CSF-1R emactuzumab 与抗 PD-L1 atezolizumab 联合用于既往未接受过或已接受过免疫检查点阻断治疗的晚期实体瘤患者

Gomez-Roca, Carlos; Cassier, Philippe; Zamarin, Dmitriy; Machiels, Jean-Pascal; Perez Gracia, Jose Luis; Stephen Hodi, F; Taus, Alvaro; Martinez Garcia, Maria; Boni, Valentina; Eder, Joseph P; Hafez, Navid; Sullivan, Ryan; Mcdermott, David; Champiat, Stephane; Aspeslagh, Sandrine; Terret, Catherine; Jegg, Anna-Maria; Jacob, Wolfgang; Cannarile, Michael A; Ries, Carola; Korski, Konstanty; Michielin, Francesca; Christen, Randolph; Babitzki, Galina; Watson, Carl; Meneses-Lorente, Georgina; Weisser, Martin; Rüttinger, Dominik; Delord, Jean-Pierre; Marabelle, Aurelien

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

抗 CSF-1R 抗体 emactuzumab 联合 CD40 激动剂 selicrelumab 治疗晚期实体瘤患者的 Ib 期研究

Machiels, Jean-Pascal; Gomez-Roca, Carlos; Michot, Jean-Marie; Zamarin, Dmitriy; Mitchell, Tara; Catala, Gaetan; Eberst, Lauriane; Jacob, Wolfgang; Jegg, Anna-Maria; Cannarile, Michael A; Watson, Carl; Babitzki, Galina; Korski, Konstanty; Klaman, Irina; Teixeira, Priscila; Hoves, Sabine; Ries, Carola; Meneses-Lorente, Georgina; Michielin, Francesca; Christen, Randolph; Rüttinger, Dominik; Weisser, Martin; Delord, Jean-Pierre; Cassier, Philippe

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

一项针对晚期/转移性实体瘤患者的emactuzumab单药或联合紫杉醇治疗的I期研究显示,免疫抑制性M2样巨噬细胞被清除。

Gomez-Roca, C A; Italiano, A; Le Tourneau, C; Cassier, P A; Toulmonde, M; D'Angelo, S P; Campone, M; Weber, K L; Loirat, D; Cannarile, M A; Jegg, A-M; Ries, C; Christen, R; Meneses-Lorente, G; Jacob, W; Klaman, I; Ooi, C-H; Watson, C; Wonde, K; Reis, B; Michielin, F; Rüttinger, D; Delord, J-P; Blay, J-Y

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

癌症治疗中的集落刺激因子1受体(CSF1R)抑制剂

Cannarile, Michael A; Weisser, Martin; Jacob, Wolfgang; Jegg, Anna-Maria; Ries, Carola H; Rüttinger, Dominik

Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5

截短的 p110 ERBB2 诱导乳腺上皮细胞迁移、侵袭和原位异种移植形成,并与磷酸化 STAT5 的丢失有关

T M Ward, E Iorns, X Liu, N Hoe, P Kim, S Singh, S Dean, A-M Jegg, M Gallas, C Rodriguez, M Lippman, R Landgraf, M D Pegram